Inhibition of Y box binding protein 1 suppresses cell growth and motility in colorectal cancer.
Although chemo- or radio-therapy is usually performed in colorectal cancer (CRC) patients, the response is highly variable in locally rectal cancer. Therefore, additional studies are needed on predictable markers and the molecular mechanisms of chemo- and radio-therapy. Y box binding protein 1 (YB1) is an oncoprotein that is aberrantly expressed in many cancers, including CRC. However, to date there are no targeting agents or strategies to inhibit YB1 expression. Here, we investigate the oncogenic function of YB1 in CRC and methods to control its expression. We observed that YB1 expression level is correlated with CRC survival rate. Moreover, YB1 overexpression was associated with CRC lymph node metastasis and invasion. We also found that radiation exposure increased YB1 expression, which led to radio-resistant CRC, mediated through the activation of cancer stem cell marker CD44 and PI3K/AKT/mTOR signaling. This study revealed, by both in vitro and in vivo assays, that depletion of YB1 could reduce cell proliferation and motility in CRC. We further demonstrated that the PI3K/mTOR inhibitor BEZ235 suppressed YB1 expression and enhanced the cytotoxicity of radiation. In addition, combined treatment with BEZ235 and radiation showed a significant anti-tumor response in an in vivo mouse xenograft model. Taken together, our results provide evidence that the activation of YB1 is a major factor in radio-resistance and suggest that targeting YB1-mediated signaling is a promising therapeutic strategy for CRC.